X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs DIVIS LABORATORIES - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD DIVIS LABORATORIES LUPIN LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 20.1 28.9 69.6% View Chart
P/BV x 2.7 5.0 54.4% View Chart
Dividend Yield % 0.9 1.0 92.9%  

Financials

 LUPIN LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
DIVIS LABORATORIES
Mar-17
LUPIN LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7501,222 143.2%   
Low Rs1,384784 176.5%   
Sales per share (Unadj.) Rs387.4153.1 253.0%  
Earnings per share (Unadj.) Rs56.639.9 141.8%  
Cash flow per share (Unadj.) Rs76.844.6 172.3%  
Dividends per share (Unadj.) Rs7.5010.00 75.0%  
Dividend yield (eoy) %0.51.0 48.0%  
Book value per share (Unadj.) Rs298.9201.8 148.1%  
Shares outstanding (eoy) m451.58265.47 170.1%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.06.6 61.7%   
Avg P/E ratio x27.725.1 110.2%  
P/CF ratio (eoy) x20.422.5 90.7%  
Price / Book Value ratio x5.25.0 105.5%  
Dividend payout %13.225.0 52.9%   
Avg Mkt Cap Rs m707,513266,266 265.7%   
No. of employees `00016.89.7 172.5%   
Total wages/salary Rs m28,4954,687 607.9%   
Avg. sales/employee Rs Th10,418.34,175.0 249.5%   
Avg. wages/employee Rs Th1,697.0481.5 352.4%   
Avg. net profit/employee Rs Th1,523.01,089.3 139.8%   
INCOME DATA
Net Sales Rs m174,94340,643 430.4%  
Other income Rs m1,065749 142.2%   
Total revenues Rs m176,00841,392 425.2%   
Gross profit Rs m44,93114,460 310.7%  
Depreciation Rs m9,1221,233 739.7%   
Interest Rs m1,52523 6,749.1%   
Profit before tax Rs m35,34913,953 253.3%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,7853,349 292.2%   
Profit after tax Rs m25,57510,604 241.2%  
Gross profit margin %25.735.6 72.2%  
Effective tax rate %27.724.0 115.3%   
Net profit margin %14.626.1 56.0%  
BALANCE SHEET DATA
Current assets Rs m119,54240,105 298.1%   
Current liabilities Rs m61,2066,595 928.1%   
Net working cap to sales %33.382.5 40.4%  
Current ratio x2.06.1 32.1%  
Inventory Days Days76119 64.1%  
Debtors Days Days9081 111.4%  
Net fixed assets Rs m131,66019,995 658.5%   
Share capital Rs m903531 170.1%   
"Free" reserves Rs m134,07353,043 252.8%   
Net worth Rs m134,97653,574 251.9%   
Long term debt Rs m56,4780-   
Total assets Rs m266,07361,585 432.0%  
Interest coverage x24.2618.4 3.9%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.70.7 99.6%   
Return on assets %10.217.3 59.0%  
Return on equity %18.919.8 95.7%  
Return on capital %19.326.1 73.9%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m81,88535,384 231.4%   
Fx outflow Rs m21,50610,399 206.8%   
Net fx Rs m60,37824,985 241.7%   
CASH FLOW
From Operations Rs m41,14811,493 358.0%  
From Investments Rs m-25,287-11,372 222.4%  
From Financial Activity Rs m4,332-93 -4,652.8%  
Net Cashflow Rs m20,19328 71,100.4%  

Share Holding

Indian Promoters % 46.6 52.0 89.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 11.8 95.8%  
FIIs % 31.9 19.0 167.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.2 58.7%  
Shareholders   98,259 31,796 309.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS